BR9913765A - Composition, use of composition, method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit - Google Patents
Composition, use of composition, method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kitInfo
- Publication number
- BR9913765A BR9913765A BR9913765-8A BR9913765A BR9913765A BR 9913765 A BR9913765 A BR 9913765A BR 9913765 A BR9913765 A BR 9913765A BR 9913765 A BR9913765 A BR 9913765A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- treatment
- kit
- improving
- pharmaceutical formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 abstract 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSIçãO, USO DA COMPOSIçãO, MéTODO PARA O TRATAMENTO DE DISTúRBIOS MEDIADOS POR 5-HT, MéTODO DE MELHORIA DO INìCIO DA AçãO TERAPêUTICA, FORMULAçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DA COMPOSIçãO, E, KIT". A invenção refere-se a uma composição compreendendo um primeiro componente (a) que é hidrogeno-(2R,3R)-tartarato de (R)-3-N,N-diciclo-butil-amino-8-fluoro-3,4,di-hidro-2H-1-benzopiran-5- carboxamida mono-hidratado e um segundo componente (b) que é 1-[3-(dimetil-amino)-propil]-1-(p-fluoro-fenil)-5-ftalancarbonitrila, como o racemato ou um seu enanciómero, na forma de uma base livre, ou um seu solvato e/ou sal farmaceuticamente aceitável, à sua preparação, às formulações farmacêuticas contendo a citada composição, ao uso da mesma e a um Método de tratamento de distúrbios afetivos, tais como distúrbios de humor e distúrbios de ansiedade, com a citada composição bem como com um kit contendo a citada composição."COMPOSITION, USE OF COMPOSITION, METHOD FOR THE TREATMENT OF DISTURBES MEDIATED BY 5-HT, METHOD OF IMPROVING THE START OF THERAPEUTIC ACTION, PHARMACEUTICAL FORMULATION, PROCESS FOR THE PREPARATION OF COMPOSITION, AND, KIT". The invention relates to a composition comprising a first component (a) which is (R) -3-N, N-dicyclo-butyl-amino-8-fluoro-3,4 hydrogen (2R, 3R) , dihydro-2H-1-benzopyran-5-carboxamide monohydrate and a second component (b) which is 1- [3- (dimethyl-amino) -propyl] -1- (p-fluoro-phenyl) - 5-phthalancarbonitrile, such as the racemate or an enantiomer, in the form of a free base, or a solvate and / or pharmaceutically acceptable salt thereof, to its preparation, to the pharmaceutical formulations containing the said composition, to the use thereof and to a Method of treatment of affective disorders, such as mood disorders and anxiety disorders, with said composition as well as with a kit containing said composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803157A SE9803157D0 (en) | 1998-09-16 | 1998-09-16 | A new composition |
| PCT/SE1999/001598 WO2000015219A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9913765A true BR9913765A (en) | 2001-06-05 |
Family
ID=20412628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9913765-8A BR9913765A (en) | 1998-09-16 | 1999-09-13 | Composition, use of composition, method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1121119A1 (en) |
| JP (1) | JP2002524509A (en) |
| KR (1) | KR20010099648A (en) |
| CN (1) | CN1317963A (en) |
| AR (1) | AR023657A1 (en) |
| AU (1) | AU6378199A (en) |
| BR (1) | BR9913765A (en) |
| CA (1) | CA2342585A1 (en) |
| CZ (1) | CZ2001962A3 (en) |
| EE (1) | EE200100156A (en) |
| HU (1) | HUP0103569A3 (en) |
| ID (1) | ID28359A (en) |
| IL (1) | IL141520A0 (en) |
| IS (1) | IS5877A (en) |
| NO (1) | NO20011313L (en) |
| PL (1) | PL346769A1 (en) |
| SE (1) | SE9803157D0 (en) |
| SK (1) | SK3272001A3 (en) |
| TR (1) | TR200100769T2 (en) |
| WO (1) | WO2000015219A1 (en) |
| ZA (1) | ZA200101951B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (en) | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | TREATMENT OF NEUROTIC DISORDERS |
| WO2002030405A2 (en) | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| WO2006038217A1 (en) * | 2004-10-05 | 2006-04-13 | Strides Acrolab Limited | An improved drug delivery system of citalopram hydrobromide and process for producing the same |
| US20110196032A1 (en) | 2005-05-20 | 2011-08-11 | Ashish Gogia | Pharmaceutical Dosage Form of an Antidepressant |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501567D0 (en) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
-
1998
- 1998-09-16 SE SE9803157A patent/SE9803157D0/en unknown
-
1999
- 1999-09-13 IL IL14152099A patent/IL141520A0/en unknown
- 1999-09-13 JP JP2000569803A patent/JP2002524509A/en active Pending
- 1999-09-13 PL PL99346769A patent/PL346769A1/en unknown
- 1999-09-13 ID IDW20010580A patent/ID28359A/en unknown
- 1999-09-13 CA CA002342585A patent/CA2342585A1/en not_active Abandoned
- 1999-09-13 EE EEP200100156A patent/EE200100156A/en unknown
- 1999-09-13 EP EP99951320A patent/EP1121119A1/en not_active Withdrawn
- 1999-09-13 AU AU63781/99A patent/AU6378199A/en not_active Abandoned
- 1999-09-13 TR TR2001/00769T patent/TR200100769T2/en unknown
- 1999-09-13 CZ CZ2001962A patent/CZ2001962A3/en unknown
- 1999-09-13 BR BR9913765-8A patent/BR9913765A/en not_active Application Discontinuation
- 1999-09-13 KR KR1020017003338A patent/KR20010099648A/en not_active Withdrawn
- 1999-09-13 WO PCT/SE1999/001598 patent/WO2000015219A1/en not_active Ceased
- 1999-09-13 SK SK327-2001A patent/SK3272001A3/en unknown
- 1999-09-13 HU HU0103569A patent/HUP0103569A3/en unknown
- 1999-09-13 CN CN99811007A patent/CN1317963A/en active Pending
- 1999-09-15 AR ARP990104627A patent/AR023657A1/en unknown
-
2001
- 2001-03-05 IS IS5877A patent/IS5877A/en unknown
- 2001-03-08 ZA ZA200101951A patent/ZA200101951B/en unknown
- 2001-03-15 NO NO20011313A patent/NO20011313L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1317963A (en) | 2001-10-17 |
| AR023657A1 (en) | 2002-09-04 |
| ZA200101951B (en) | 2002-06-10 |
| IL141520A0 (en) | 2002-03-10 |
| NO20011313D0 (en) | 2001-03-15 |
| EE200100156A (en) | 2002-08-15 |
| CZ2001962A3 (en) | 2001-08-15 |
| TR200100769T2 (en) | 2001-11-21 |
| NO20011313L (en) | 2001-05-16 |
| CA2342585A1 (en) | 2000-03-23 |
| IS5877A (en) | 2001-03-05 |
| HUP0103569A3 (en) | 2002-03-28 |
| EP1121119A1 (en) | 2001-08-08 |
| HUP0103569A2 (en) | 2002-02-28 |
| SK3272001A3 (en) | 2001-09-11 |
| WO2000015219A1 (en) | 2000-03-23 |
| ID28359A (en) | 2001-05-17 |
| PL346769A1 (en) | 2002-02-25 |
| JP2002524509A (en) | 2002-08-06 |
| AU6378199A (en) | 2000-04-03 |
| SE9803157D0 (en) | 1998-09-16 |
| KR20010099648A (en) | 2001-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Menza et al. | Modafinil augmentation of antidepressant treatment in depression | |
| Detke et al. | Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial | |
| CA2532859C (en) | Use of rotigotine for the treatment of depression | |
| SE9501567D0 (en) | A new combination | |
| BR0312216A (en) | Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject suffering from a disease or condition and product combination | |
| BR9810773A (en) | Use of a long-acting local anesthetic ingredient, pharmaceutical composition, use of a local anesthetic, and, kit | |
| BR0211201A (en) | Compound, process for preparing such compound, use thereof, pharmaceutical composition comprising the same and method for treating a disease in a mammal | |
| BR9812088A (en) | Combination of components, use of this, processes for its preparation, for the treatment of affective disorders, for the treatment of depression, and to improve the beginning of therapeutic action, pharmaceutical formulation, and, kit | |
| BR0207802A (en) | Use of inverse gabaa agonists in combination with nicotine receptor partial agonists, estrogens, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders. | |
| BR0112661A (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation | |
| BR0309933A (en) | (s) -4-amino-5-chloro-2-methoxy-n- [1- [1- (1- (2-tetrahydrofurylcarbonyl) -4-piperidinylmethyl] -4-piperidinyl] benzamide, process for their preparation, composition containing the same and intermediates obtained in this way | |
| BR9812236A (en) | Combination of components, use of this, processes for its preparation, for the treatment of affective disorders, for the treatment of depression, and to improve the beginning of therapeutic action, pharmaceutical formulation, and, kit | |
| BR0308133A (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
| RU2005123808A (en) | CARBOSTIRYL DERIVATIVES AND SEROTONIN REVERSE INHIBITORS FOR TREATMENT OF EMOTIONAL DISORDERS | |
| BR9913765A (en) | Composition, use of composition, method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit | |
| MX2008000249A (en) | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders. | |
| BR9915951A (en) | Process for preparing a pharmaceutical composition for use as an anti-arrhythmia drug with a controlled beta-adrenergic block, pharmaceutical composition, oral and parenteral preparation for the treatment of heart disease in mammals, and method of treatment for them | |
| BRPI0713733A2 (en) | methods to lessen symptoms of depression and to treat one or more psychological conditions, pharmaceutical composition and kit | |
| BR0213949A (en) | Methods for treating depression and other snc disorders using enanciomerically enriched desmethyl and dide methyl metabolites of citalopram | |
| BR0111002A (en) | Combination of growth hormone secretagogues and antidepressants | |
| BR9913748A (en) | Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit | |
| BR9812234A (en) | Combination of components, use of this, processes for its preparation, for the treatment of affective disorders, for the treatment of depression, and to improve the beginning of therapeutic action, pharmaceutical formulation, and, kit | |
| AR033779A1 (en) | USEFUL COMPOUNDS IN REFLUX DISEASE | |
| Salin-Pascual et al. | Effects of veniafaxine in the sleep architecture of rats | |
| JP2004523495A (en) | Synthesis, use and compositions of hydroxylated cyclobutylalkylamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |